The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More
News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW. This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer. The… Read More
Researchers have uncovered the genetic basis of multiple primary lung cancers, shedding light on potential therapeutic targets for treatment. A team of researchers, led by Professor Motoshi Suzuki from the Department of Molecular Oncology, Fujita Health University, Japan, along with graduate student Dat Quoc Tran from the university, distinguished… Read More
A team of researchers from ChristianaCare and the University of Delaware in the US has uncovered that a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal process, causing immature cells to build up, tissue structure to break down and early tumours to form. … Read More
A common gene mutation could be the cause of tumours forming in colorectal cancer patients, a new study suggests. A team of researchers from ChristianaCare and the University of Delaware uncovered how a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal… Read More
Duchenne UK has awarded £500,000 ($653,000) to biotech company MyoGene Bio to support the development of an innovative gene editing therapy for Duchenne muscular dystrophy (DMD). The funding is part of Duchenne UK’s Therapeutic Call, a competitive initiative designed to support innovative research with the potential to deliver new treatments… Read More
The US Food and Drug Administration (FDA) has approved Eli Lilly’s Inluriyo (imlunestrant, 200mg tablets), an oral oestrogen receptor antagonist. It is approved for the treatment of adults with oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose… Read More
A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer. The study was led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and… Read More
The European Commission (EC) has granted approval for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages six years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Thousands of people with CF across… Read More
A clinical trial for early-stage breast cancer patients with BRCA gene mutations has reported 100% survival after three years. In a Phase III trial, Cancer Research UK researchers stopped BRCA-linked breast cancers growing or coming back by giving patients olaparib tablets 48 hours after each chemotherapy dose. … Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s round-up highlights the vital role of genetics in drug discovery, including new data… Read More
News round-up for 9-13 June by DDW Senior Digital Content Editor Diana Spencer. This week’s round-up highlights the vital role of genetics in drug discovery, including new data for an Alzheimer’s gene therapy, the discovery of a genetic target for rejuvenation therapies, and a 13-year follow up on… Read More
Dox – comprising of doxecitine and doxribtimine – to treat thymidine kinase 2 deficiency (TK2d) has been granted Promising Innovative Medicine (PIM) designation in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA). TK2d is caused by a genetic mutation in the TK2 gene. This… Read More
A team of international researchers have secured £1.5 ($1.9) million funding from Cancer Research UK (CRUK) to study the genetic secrets of childhood cancer neuroblastoma. The project will be led by scientists at the University of Sheffield, alongside colleagues from The Institute of Cancer Research (ICR), Kings… Read More
Scientists have developed a tool which helps them better understand cancer’s survival tactics and could eventually lead to new treatments for dozens of cancers. ‘Synthetic lethality’, the tactic of blocking pathways that cancer cells rely on, has so far mainly been successful in patients with BRCA-mutated breast,… Read More
Final draft guidance from the UK’s National Institute for Health and Care Excellence (NICE) recommends the use of elacestrant, the first tailored treatment for locally advanced and metastatic breast cancer with mutations in the ESR1 gene. Specifically, the drug will be available on the NHS to treat post-menopausal women, and… Read More
